Invictus RG Reduces Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Invictus RG lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,214 shares of the medical equipment provider’s stock after selling 182 shares during the period. Invictus RG’s holdings in Zimmer Biomet Holdings were worth $392,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in ZBH. Cibc World Markets Corp raised its position in shares of Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock worth $2,565,000 after buying an additional 7,269 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Zimmer Biomet Holdings by 6.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider’s stock worth $737,000 after buying an additional 450 shares during the last quarter. Auxier Asset Management raised its position in shares of Zimmer Biomet Holdings by 3.3% in the fourth quarter. Auxier Asset Management now owns 86,514 shares of the medical equipment provider’s stock worth $8,928,000 after buying an additional 2,750 shares during the last quarter. DnB Asset Management AS raised its position in shares of Zimmer Biomet Holdings by 16.2% in the first quarter. DnB Asset Management AS now owns 22,208 shares of the medical equipment provider’s stock worth $2,712,000 after buying an additional 3,100 shares during the last quarter. Finally, Israel Discount Bank of New York purchased a new position in shares of Zimmer Biomet Holdings during the first quarter worth approximately $721,000. Institutional investors and hedge funds own 84.34% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) opened at 127.11 on Monday. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.21. The firm has a market cap of $25.63 billion, a P/E ratio of 52.03 and a beta of 1.21. The company’s 50-day moving average price is $123.43 and its 200 day moving average price is $117.75.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.02. The business had revenue of $1.98 billion for the quarter, compared to analysts’ expectations of $1.96 billion. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.00 earnings per share. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.54 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Shareholders of record on Friday, June 23rd will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.76%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 39.67%.

WARNING: “Invictus RG Reduces Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)” was posted by WKRB News and is owned by of WKRB News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.wkrb13.com/markets/2284796/invictus-rg-reduces-stake-in-zimmer-biomet-holdings-inc-nysezbh.html.

A number of brokerages have commented on ZBH. Jefferies Group LLC reiterated a “buy” rating and issued a $148.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, June 30th. Cantor Fitzgerald began coverage on Zimmer Biomet Holdings in a research report on Thursday, June 29th. They issued a “neutral” rating and a $137.00 price objective on the stock. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Royal Bank of Canada increased their price objective on Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research report on Wednesday, June 21st. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Friday, April 28th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $138.31.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Chad F. Phipps sold 6,200 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $116.76, for a total transaction of $723,912.00. The disclosure for this sale can be found here. Insiders have sold 111,262 shares of company stock worth $13,103,927 in the last ninety days. Insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284796/invictus-rg-reduces-stake-in-zimmer-biomet-holdings-inc-nysezbh.html

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.